Improvements in antiretroviral therapy outcomes over calendar time

Current Opinion in HIV and AIDS

Volumn 4, Issue 3, 2009, Pages 194-199

  Boyd, Mark A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Calendar time; Cohort; Combination antiretroviral therapy; Outcome; Randomized controlled trail

Indexed keywords

ABACAVIR; ABACAVIR PLUS EMTRICITABINE; ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CLINICAL TRIAL; COMBINATION ANTIRETROVIRAL THERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIROTHERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; METHODOLOGY; PROGNOSIS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; PROGNOSIS; TREATMENT OUTCOME;

EID: 67651151188     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328329fc8d     Document Type: Review

References (46)

1. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997; 315:1194-1199.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
3. Correll PK, Law MG, McDonald AM, et al. HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust 1998; 169:469-472. (Pubitemid 28497726)
4. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
5. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95. This paper is the first report to suggest a substantially increased life expectancy in HIV-infected people receiving cART.
6. Hogg R, Lima V, Sterne JA, et al., Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in highincome countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299. This paper describes a large and influential international, multicohort study that confirmed the single-cohort findings of Lohse et al. [5].
7. Lampe FC, Gatell JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166:521-528.
8. Bannister WP, Kirk O, Gatell JM, et al. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr 2006; 42:229-237. (Pubitemid 43884719)
9. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868. (Pubitemid 29126872)
10. Vo TT, Ledergerber B, Keiser O, et al. Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. J Infect Dis 2008; 197:1685-1694.
11. Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS 2005; 19:815-822. (Pubitemid 40834752)
12. Moore RD, Keruly JC, Gebo KA, Lucas GM. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005; 39:195-198.
13. Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22: 1951-1960.
14. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009. [Epub ahead of print] A meta-analysis that suggests that once-daily cART regimens are associated with a moderately improved rate of treatment adherence than regimens requiring more frequent dosing.
15. Phillips AN, Pradier C, Lazzarin A, et al. Viral load outcome of nonnucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviralexperienced patients. AIDS 2001; 15:2385-2395. (Pubitemid 34014607)
16. Mocroft A, Phillips AN, Friis-Møller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther 2002; 7:21-30. (Pubitemid 36285548)
17. Porter K, Walker S, Hill T, et al. Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 cells/mm3. J Acquir Immune Defic Syndr 2008; 47:202-205. (Pubitemid 351172187)
18. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15:1369-1377. (Pubitemid 32663904)
19. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20:2051-2064.
20. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046. (Pubitemid 34680595)
21. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
22. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
23. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106. An influential RCT that demonstrated that an EFV-containing initial NNRTI and two N(t)RTI cART regimens produce superior virological outcome to a boosted protease inhibitor and two N(t)RTI regimens containing boosted lopinavir, but that failure of the NNRTI and two N(t)RTI is more likely to be associated with drug resistance across two ART classes. (Pubitemid 351679596)
24. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865-1873.
25. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
26. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIVinfected adults. Clin Infect Dis 2004; 39:1038-1046. (Pubitemid 39313463)
27. Martinez E, Arranz JA, Podzamczer D, et al. Efficacy and safety of NRTIs switch to tenofovir plus emtricitabine (truvada) vs. abacavir plus lamivudine (kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: the BICOMBO study [abstract #WESS102]. In: Program and abstracts of the 4th International AIDS Society Conference on HIV pathogenesis, treatment and prevention; 22-25 July 2007; Sydney, Australia.
28. SaxP, Tierney C, CollierA, et al.ACTG5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA 100 000 c/ml [abstract #THAB0303]. In: Program and abstracts of the XVII International AIDS Conference; 3-8 August 2008; Mexico City, Mexico.
29. Hill A, Sawyer W. Effects of either an ABC/3TC of TDF/FTC N(t)RTI backbone on the efficacy of first-line boosted PI based HAART: systematic review of 12 clinical trials in 4896 patients [abstract #H-1254]. In: Program and abstracts of the 49th ICAAC annual meeting; 25-28 October 2008; Washington, DC.
30. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed 19December 2008]
31. Sabin CA, Worm SW, Weber R, et al., D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and the risk of myocardial infarction in HIVinfected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426. This paper is the first systematic report to link ABC use with an increased risk of myocardial infarction.
32. Lundgren JD, Neuhaus J, Babiker A, et al., The SMART/INSIGHT and the D:A:D study groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
33. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195. (Pubitemid 36618129)
34. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185; Erratum in: N Engl J Med 2003; 349:1100. (Pubitemid 36618128)
35. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimized background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the randomized evaluation of strategic intervention in multidrug resistant patients with tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-475. (Pubitemid 44142769)
36. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369:1169-1178; Erratum in: Lancet 2008; 371:116. (Pubitemid 46541620)
37. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
38. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
39. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30; Erratum in: Ann Intern Med 2002; 136:253. (Pubitemid 30432540)
40. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941.
41. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-573. (Pubitemid 351650537)
42. Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24:1263-1268.
43. Shuter J. Forgiveness of nonadherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother 2008; 61:769-773.
44. Keiser O, Orrell C, Egger M, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5:e148.
45. Nsutebu EF, Hunter ER. Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother 2008; 62:464-468.
46. Lohse N, Obel N, Kronborg G, et al. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997- 2004. Antivir Ther 2006; 11:591-600.